MyoGene Bio

2:00 PM - 3:00 PM (PDT), Tuesday, June 14, 2022
MyoGene Bio is dedicated to developing cutting edge therapies for muscle diseases. Our first approach, MyoDys45-55, is a gene editing therapy for Duchenne muscular dystrophy, a devastating muscle wasting disease. MyoDys45-55 permanently removes mutations that cause Duchenne for ~50% of patients to restore the dystrophin protein while retaining significantly more of the protein than other gene therapy approaches.
Co-founder and CEO
MyoGene Bio